Medline Inc. (MDLN) Free cash flow
- Free cash flow · 12 months (USD): Value $1.55B; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-27..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-27..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-27..
- Free cash flow margin · 12 months: Value 5.16%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-27..
Free cash flow
Overview →Financial period ending 2026-06-27; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $1.55B | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-27. $1.99B − $446.00M ≈ $1.55B |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-27. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-27. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | 5.16% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-27. $1.55B ÷ $29.94B × 100 ≈ 5.16% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-27. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $1.99B | Cash generated by operating activities. Period ending 2026-06-27. |
| Operating cash flow / net income · 12 months | (m) | Operating cash flow / net income. Period ending 2026-06-27. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | 1.99B USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 446.00M USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | 1.55B USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 29.94B USD | |
| Quarter-end shares | (m) | |
| Net income | (m) | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-27 | $1.55B | (m) | $1.99B | $446.00M | (m) | $29.94B | (m) | (m) | (m) | (m) | 5.16% | (m) |
| 2026-03-28 | $1.03B | (m) | $1.47B | $445.00M | (m) | $29.14B | (m) | (m) | (m) | (m) | 3.53% | (m) |
| 2025-12-31 | $1.30B | (m) | $1.74B | $447.00M | (m) | $28.43B | (m) | $1.16B | (m) | (m) | 4.56% | 1.50× |
| 2025-06-28 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-29 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $1.42B | (m) | $1.77B | $354.00M | (m) | $25.51B | (m) | (m) | (m) | (m) | 5.55% | (m) |
| 2023-12-31 | $1.41B | (m) | $1.69B | $275.00M | (m) | $23.23B | (m) | (m) | (m) | (m) | 6.07% | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.